Literature DB >> 1693748

Effects of the beta 2-adrenoceptor agonist, clenbuterol, on muscle atrophy due to food deprivation in the rat.

J J Choo1, M A Horan, R A Little, N J Rothwell.   

Abstract

The effects of a beta 2-adrenoceptor agonist, clenbuterol, on body weight and protein metabolism of gastrocnemius muscle, heart, and liver were studied in rats subjected to 50% food restriction or fasting. Food restriction by 50% for 7 days caused a complete cessation of growth and reductions in the mass, protein, and RNA content of muscle, heart, and liver. The ratio of RNA to protein content was also suppressed in muscle and heart, but not in liver. Fasting for 3 days caused loss of body weight (BW), reductions in the mass, protein, and RNA content, and the ratio of RNA to protein of gastrocnemius muscle, heart, and liver. Oral administration of clenbuterol (approximately 0.6 mg/kg BW/d) to food-restricted animals did not affect BW, but did increase in the mass, protein, and RNA content, and the ratio of RNA to protein of gastrocnemius muscle. The protein content of heart was also increased. Twice-daily injections of clenbuterol (2 mg/kg body weight/d) to fasting animals had no effect on BW or the mass or protein content of gastrocnemius muscle or liver, but both parameters were stimulated in heart. The results indicate that the anabolic action of clenbuterol are maintained when substrate availability is reduced by food restriction, but this effect is lost during severe protein and energy deficit (fasting).

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1693748     DOI: 10.1016/0026-0495(90)90034-a

Source DB:  PubMed          Journal:  Metabolism        ISSN: 0026-0495            Impact factor:   8.694


  3 in total

1.  Affinity of clenbuterol analogues for beta 2-adrenoceptors in bovine skeletal muscle and the effect of these compounds on urinary nitrogen excretion in female rats.

Authors:  M N Sillence; G G Pegg; D B Lindsay
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1991-10       Impact factor: 3.000

2.  Phase I/II trial of formoterol fumarate combined with megestrol acetate in cachectic patients with advanced malignancy.

Authors:  C A Greig; N Johns; C Gray; A MacDonald; N A Stephens; R J E Skipworth; M Fallon; L Wall; G M Fox; K C H Fearon
Journal:  Support Care Cancer       Date:  2014-01-04       Impact factor: 3.603

Review 3.  The impact of catecholamines on skeletal muscle following massive burns: Friend or foe?

Authors:  Elizabeth Blears; Evan Ross; John O Ogunbileje; Craig Porter; Andrew J Murton
Journal:  Burns       Date:  2021-02-02       Impact factor: 2.609

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.